Drugs / Sitravatinib
Sitravatinib
also known as
MGCD516 · MG-516 · MG-91516 · MGCD-516 L-MALATE · MGCD-516 MALATE SALT · Sitravatinib l-malate · sitravatinib malate
Small molecule targets AXL, DDR2, FLT3, KIT, MERTK, MET, RET, TYRO3 via inhibition
Trials 34
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03575598 | Aug 2018 → Feb 2020 | oral cavity squamous cell carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 18 trials | ||||||
| Phase 1 | NCT04935112 | Jul → Aug 2021 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04887194 | Apr 2021 → Dec 2022 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04800614 | Mar → Jul 2021 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04772612 | Mar 2021 → Jul 2022 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04518046 | Aug 2020 → Jun 2023 | clear cell renal carcinoma | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04472650 | Jul → Nov 2020 | neoplasm | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT03666143 | Nov 2018 → Jan 2023 | cancer | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT02219711 | Aug 2014 → Apr 2022 | cancer of unknown primary site | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03941873 | Feb 2019 → Mar 2023 | gastroesophageal junction adenocarcinoma, hepatocellular carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 1/2 | NCT03015740 | Apr 2017 → Sep 2022 | clear cell renal carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 218 trials | ||||||
| Phase 2 | NCT05614453 | Jun 2023 | cervical cancer | Australia New Zealand Gynaecological Oncology Group | Withdrawn | No outcome recorded |
| Phase 2 | NCT05461794 | Oct 2022 → Feb 2024 | esophageal squamous cell carcinoma | BeiGene | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05542342 | Sep 2022 → Dec 2023 | uveal melanoma | Spanish Melanoma Group | Completed | No outcome recorded |
| Phase 2 | NCT05419817 | Sep 2022 → Jul 2025 | endometrial cancer | Haider Mahdi | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT05407519 | Jul 2022 → Jun 2026 | hepatocellular carcinoma | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04904302 | May 2022 → Mar 2026 | clear cell renal carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05228496 | Mar 2022 → Jul 2023 | small cell lung carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04925986 | Feb 2022 → Jun 2023 | non-small cell lung carcinoma | Sarah Goldberg | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05104801 | Nov 2021 → Sep 2023 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04123704 | Sep 2021 → Jan 2023 | triple-negative breast carcinoma | Xiang Zhang | Terminated | No outcome recorded |
| Phase 2 | NCT04734262 | Apr 2021 → Jun 2026 overdue | breast cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05176925 | Jan 2021 → Jun 2022 | non-small cell lung carcinoma | Fudan University | Terminated | No outcome recorded |
| Phase 2 | NCT04727996 | Nov 2020 → Jul 2023 | biliary tract cancer | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03680521 | Oct 2018 → Apr 2020 | clear cell renal carcinoma | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03606174 | Sep 2018 → Aug 2022 | ureter transitional cell carcinoma, urethra transitional cell carcinoma, urinary bladder cancer | Mirati Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02954991 | Nov 2016 → Nov 2021 | non-small cell lung carcinoma | Mirati Therapeutics Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02978859 | Nov 2016 → Jan 2020 | liposarcoma | Columbia University | Completed | No outcome recorded |
| Phase 2 | NCT02664935 | May 2015 → Nov 2023 | adenocarcinoma, non-small cell lung carcinoma, squamous cell carcinoma | University of Birmingham | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04887870 | Jun 2021 → Apr 2025 | cancer of unknown primary site | Mirati Therapeutics Inc. | Completed | No outcome recorded |
| Phase 34 trials · 1 missed | ||||||
| Phase 3 | NCT05564338 | Jun 2023 → Apr 2027 | hepatocellular carcinoma | BeiGene | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT04921358 | Jul 2021 → Dec 2023 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
| Phase 3 | NCT03906071 | Jul 2019 → Mar 2023 | non-small cell lung carcinoma | Mirati Therapeutics Inc. | Terminated | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05255276 Comparator | Feb → May 2022 | — | Mirati Therapeutics Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-11 | BeOne Medicines | Results BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021 beonemedicines.com ↗
The combination showed preliminary antitumor activity in patients with unresectable or metastatic melanoma refractory or resistant to PD-1/L1 inhibitors and platinum-resistant ovarian cancer in an ongoing Phase 1b clinical trial, with a generally well-tolerated safety profile. |
| 2019-12-13 | BeOne Medicines | Results BeiGene Announces Clinical Data on Investigational Anti-PD-1 Antibody Tislelizumab in Combination with Sitravatinib at European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2019 beonemedicines.com ↗ |
All press releases naming this drug 3 releases
Evidence & citations 16 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sitravatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03941873 ↗ |
| Known as | MG-516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989926 ↗ |
| Known as | MG-91516 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989926 ↗ |
| Known as | MGCD-516 L-MALATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989926 ↗ |
| Known as | MGCD-516 MALATE SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989926 ↗ |
| Known as | MGCD516 | “Sitravatinib (MGCD516) is an orally-available, potent small molecule inhibitor of a closely related spectrum of tyrosine kinases, which has shown antitumor activity in a...” NCT03575598 ↗3“efficacy (defined as achieving complete remission, partial remission, or stable disease within 6 weeks) of sitravatinib (MGCD516) when administered orally (PO) daily” NCT03015740 ↗ |
| Known as | Sitravatinib l-malate | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989926 ↗ |
| Known as | sitravatinib malate | “A single-dose administration of sitravatinib malate 50 mg on Day 1.” NCT05255276 ↗ |
| Action | Inhibit | “MGCD516 is a small molecule inhibitor of several closely related receptor tyrosine kinases.” NCT02219711 ↗ |
| Modality | Small molecule | “MGCD516 is a small molecule inhibitor” NCT02219711 ↗ |
| Route | Oral | “MGCD516 is orally administered to patients with advanced solid tumor malignancies” NCT02219711 ↗ |
| Target | AXL | “MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the...” NCT02219711 ↗ |
| Target | DDR2 | “MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the...” NCT02219711 ↗ |
| Target | MERTK | “Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK)” PMID 35767205 ↗ Jun 2022 |
| Target | MET | “MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the...” NCT02219711 ↗ |
| Target | TYRO3 | “Sitravatinib (MGCD516), a spectrum-selective receptor tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MERTK)” PMID 35767205 ↗ Jun 2022 |